FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes

Forkhead box M1 (FOXM1) is a late cell cycle gene that plays a crucial role in carcinogenesis and chemotherapeutic drug resistance. In this study, the impact of FOXM1 expression on patient outcome was investigated for the first time in formalin fixed and paraffin embedded (FFPE) samples of chemother...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Rinaldetti, Sébastien (VerfasserIn) , Worst, Thomas (VerfasserIn) , Weis, Cleo-Aron Thias (VerfasserIn) , Erben, Philipp (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: April 24, 2017
In: OncoTarget
Year: 2017, Jahrgang: 8, Heft: 29, Pages: 47595-47606
ISSN:1949-2553
DOI:10.18632/oncotarget.17394
Online-Zugang:Verlag, kostenfrei, Volltext: http://dx.doi.org/10.18632/oncotarget.17394
Verlag, kostenfrei, Volltext: http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=17394&path[]=55649
Volltext
Verfasserangaben:Sebastien Rinaldetti, Ralph Markus Wirtz, Thomas Stefan Worst, Markus Eckstein, Cleo Aaron Weiss, Johannes Breyer, Wolfgang Otto, Christian Bolenz, Arndt Hartmann and Philipp Erben

MARC

LEADER 00000caa a2200000 c 4500
001 1576116883
003 DE-627
005 20230427042926.0
007 cr uuu---uuuuu
008 180606s2017 xx |||||o 00| ||eng c
024 7 |a 10.18632/oncotarget.17394  |2 doi 
035 |a (DE-627)1576116883 
035 |a (DE-576)506116883 
035 |a (DE-599)BSZ506116883 
035 |a (OCoLC)1341011082 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Rinaldetti, Sébastien  |d 1988-  |e VerfasserIn  |0 (DE-588)1073669157  |0 (DE-627)829329730  |0 (DE-576)435254952  |4 aut 
245 1 0 |a FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes  |c Sebastien Rinaldetti, Ralph Markus Wirtz, Thomas Stefan Worst, Markus Eckstein, Cleo Aaron Weiss, Johannes Breyer, Wolfgang Otto, Christian Bolenz, Arndt Hartmann and Philipp Erben 
264 1 |c April 24, 2017 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.06.2018 
520 |a Forkhead box M1 (FOXM1) is a late cell cycle gene that plays a crucial role in carcinogenesis and chemotherapeutic drug resistance. In this study, the impact of FOXM1 expression on patient outcome was investigated for the first time in formalin fixed and paraffin embedded (FFPE) samples of chemotherapy naïve muscle-invasive bladder cancer (MIBC) patients. Expression analyses were performed on the Mannheim cohort (n=84) and validated on the independent Chungbuk cohort (n=61). In a Cox’ proportional hazards model, a distinct FOXM1 expression cut-off dividing both cohorts in a ‘high-risk’ and ‘low-risk’ group has been determined. Multivariate analyses showed that FOXM1 is an independent risk factor for outcome prediction superior to the TNM system. The FOXM1 ‘high-risk’ group had a 4- to 7-fold increased risk of death (p<0.03) and presented further an overexpression of MKI67. Recent studies showed that MIBCs can be subclassified in breast cancer-like subtypes: basal, luminal and p53-like. Here we demonstrated that FOXM1 was differentially expressed between MIBC subtypes concordant to its subtype specific expression in breast cancer. Since the proto-oncogene FOXM1 is known to play an important role in cisplatin resistance and to be a promising drug target, this study supports FOXM1 as a crucial biomarker in the personalization of MIBC therapy and urges prospective translational studies. 
700 1 |a Worst, Thomas  |d 1985-  |e VerfasserIn  |0 (DE-588)1028335679  |0 (DE-627)73058500X  |0 (DE-576)375827501  |4 aut 
700 1 |a Weis, Cleo-Aron Thias  |d 1985-  |e VerfasserIn  |0 (DE-588)1062803752  |0 (DE-627)806961198  |0 (DE-576)42022730X  |4 aut 
700 1 |a Erben, Philipp  |d 1973-  |e VerfasserIn  |0 (DE-588)128501014  |0 (DE-627)373920997  |0 (DE-576)297181661  |4 aut 
773 0 8 |i Enthalten in  |t OncoTarget  |d [Erscheinungsort nicht ermittelbar] : Impact Journals LLC, 2010  |g 8(2017), 29, Seite 47595-47606  |h Online-Ressource  |w (DE-627)63035975X  |w (DE-600)2560162-3  |w (DE-576)325343764  |x 1949-2553  |7 nnas  |a FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes 
773 1 8 |g volume:8  |g year:2017  |g number:29  |g pages:47595-47606  |g extent:12  |a FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes 
856 4 0 |u http://dx.doi.org/10.18632/oncotarget.17394  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=17394&path[]=55649  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20180606 
993 |a Article 
994 |a 2017 
998 |g 128501014  |a Erben, Philipp  |m 128501014:Erben, Philipp  |d 60000  |d 63100  |e 60000PE128501014  |e 63100PE128501014  |k 0/60000/  |k 1/60000/63100/  |p 10  |y j 
998 |g 1062803752  |a Weis, Cleo-Aron Thias  |m 1062803752:Weis, Cleo-Aron Thias  |d 60000  |d 63400  |e 60000PW1062803752  |e 63400PW1062803752  |k 0/60000/  |k 1/60000/63400/  |p 5 
998 |g 1028335679  |a Worst, Thomas  |m 1028335679:Worst, Thomas  |d 60000  |d 63100  |e 60000PW1028335679  |e 63100PW1028335679  |k 0/60000/  |k 1/60000/63100/  |p 3 
998 |g 1073669157  |a Rinaldetti, Sébastien  |m 1073669157:Rinaldetti, Sébastien  |d 60000  |d 61200  |e 60000PR1073669157  |e 61200PR1073669157  |k 0/60000/  |k 1/60000/61200/  |p 1  |x j 
999 |a KXP-PPN1576116883  |e 3011788219 
BIB |a Y 
SER |a journal 
JSO |a {"name":{"displayForm":["Sebastien Rinaldetti, Ralph Markus Wirtz, Thomas Stefan Worst, Markus Eckstein, Cleo Aaron Weiss, Johannes Breyer, Wolfgang Otto, Christian Bolenz, Arndt Hartmann and Philipp Erben"]},"physDesc":[{"extent":"12 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 06.06.2018"],"origin":[{"dateIssuedDisp":"April 24, 2017","dateIssuedKey":"2017"}],"title":[{"title":"FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes","title_sort":"FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes"}],"recId":"1576116883","language":["eng"],"id":{"doi":["10.18632/oncotarget.17394"],"eki":["1576116883"]},"relHost":[{"id":{"eki":["63035975X"],"zdb":["2560162-3"],"issn":["1949-2553"]},"recId":"63035975X","language":["eng"],"title":[{"title_sort":"OncoTarget","title":"OncoTarget","subtitle":"open access impact journal"}],"pubHistory":["1.2010,Mai -"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 16.08.2018"],"origin":[{"dateIssuedDisp":"2010-","dateIssuedKey":"2010","publisher":"Impact Journals LLC","publisherPlace":"[Erscheinungsort nicht ermittelbar]"}],"part":{"volume":"8","text":"8(2017), 29, Seite 47595-47606","year":"2017","pages":"47595-47606","issue":"29","extent":"12"},"physDesc":[{"extent":"Online-Ressource"}],"disp":"FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypesOncoTarget"}],"person":[{"family":"Rinaldetti","given":"Sébastien","roleDisplay":"VerfasserIn","role":"aut","display":"Rinaldetti, Sébastien"},{"display":"Worst, Thomas","family":"Worst","given":"Thomas","role":"aut","roleDisplay":"VerfasserIn"},{"display":"Weis, Cleo-Aron Thias","family":"Weis","given":"Cleo-Aron Thias","roleDisplay":"VerfasserIn","role":"aut"},{"display":"Erben, Philipp","role":"aut","roleDisplay":"VerfasserIn","given":"Philipp","family":"Erben"}]} 
SRT |a RINALDETTIFOXM1PREDI2420